Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction
CARDIOVASCULAR DRUGS AND THERAPY, vol.17, no.4, pp.371-374, 2003 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 17 Issue: 4
- Publication Date: 2003
- Doi Number: 10.1023/a:1027376529708
- Journal Name: CARDIOVASCULAR DRUGS AND THERAPY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.371-374
- Keywords: myocardial infarction, trimetazidine, exercise test, CORONARY-ARTERY DISEASE, STABLE ANGINA-PECTORIS, DOUBLE-BLIND, PROPRANOLOL, COMBINATION, DILTIAZEM, EFFICACY, RABBITS, SIZE
- Akdeniz University Affiliated: No
Abstract
Background: It was demonstrated that the novel metabolic agent, trimetazidine, could lessen the incidence and severity of angina, whether used in monotherapy or combination. Although the animal studies demonstrated that trimetazidine reduces myocardial infarct size and improves recovery of mechanic function after ischemia, little is known on the potential benefits of trimetazidine in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the efficacy of trimetazidine on AMI by sub-maximal exercise test.